Polycythaemia Vera

Polycythaemia vera (PV) is a rare, slow-growing blood cancer in which the bone marrow produces far too many red blood cells. The resulting thickening of the blood raises the risk of blood clots, stroke, and heart attack. Most cases are driven by a mutation in the JAK2 gene and are diagnosed incidentally on a routine blood count.

Medicine used to treat Polycythaemia Vera

Hydrea

Hydroxycarbamide

500mg

Developed to alleviate conditions involving abnormal blood cell growth to address long-term stability and symptom control.

From $2.17 / tablet View

Recognising the signs

Symptoms arise from sluggish, thickened blood and elevated blood pressure within the vessels. Common complaints include persistent headaches, dizziness, blurred vision, and a flushed, itchy skin, particularly after a hot bath or shower (aquagenic pruritus). Some people notice fullness or discomfort on the left side of the abdomen caused by an enlarged spleen.

Seek urgent medical attention if you experience sudden weakness on one side of the body, slurred speech, chest pain, or severe shortness of breath, these may signal a clot or stroke requiring emergency care.

How polycythaemia vera is managed

Treatment focuses on reducing blood viscosity and cutting clot risk. Regular venesection (removing a unit of blood) is the first step for many patients. When venesection alone is insufficient, cytoreductive therapy is added; hydroxycarbamide is the most widely used agent and sits within oncology support care. Low-dose aspirin is typically given alongside to thin the blood further.

PV requires lifelong monitoring by a haematologist, as a small proportion of cases can transform over time into myelofibrosis or acute leukaemia.